Core Viewpoint - The article discusses the emergence of a new health tech startup, Haemanthus, founded by Billy Evans, the partner of Elizabeth Holmes, the infamous figure behind the Theranos scandal. The company aims to innovate in health diagnostics while distancing itself from the Theranos legacy [3][4]. Group 1: Company Overview - Haemanthus is focused on animal testing and pet healthcare, with plans to expand into human diagnostics. The company was established in February 2024 and currently employs around ten staff members and several advisors, including veterinarians and diagnostic specialists [4]. - The startup has recently obtained its first patent for a small machine that uses laser technology to analyze blood, saliva, or urine samples for diseases such as cancer and infections [4][5]. Group 2: Funding and Investment Challenges - Haemanthus is seeking to raise $50 million (approximately 360 million RMB) for its operations and claims that product development will require three years and $70 million [6]. - Notable investors, including James W. Breyer and Michael Dell, have declined to invest in Haemanthus, citing concerns over the scientific validity and clinical applicability of the proposed technology [6][7]. Group 3: Background of Key Individuals - Billy Evans, the founder of Haemanthus, has a background in the hospitality industry and limited experience in biological diagnostics. His connection to Elizabeth Holmes raises concerns about the potential influence of her past on the new venture [10]. - Elizabeth Holmes, once celebrated as a visionary entrepreneur, is currently serving an 11-year prison sentence for fraud related to Theranos. Despite her incarceration, she continues to express ambitions to return to the biotech field post-release [11].